PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Front Biosci. Author manuscript; available in PMC 2010 August 4.
Published in final edited form as:
PMCID: PMC2915779
NIHMSID: NIHMS210817

Higher expression of Bax in regulatory T cells increases vascular inflammation

Abstract

This study is to examine our hypothesis that CD4+CD25highFoxp3+ regulatory T cells (Tregs) have an interleukin-2 (IL-2) withdrawal-triggered apoptosis pathway, and modulation of Treg apoptosis pathway affects development of vascular inflammation. We found that pro-apoptotic protein Bax upregulation in Tregs is induced by IL-2 withdrawal. Treg apoptosis induced by IL-2 withdrawal is inhibited by a Bax inhibitor, suggesting that highly expressed Bax is functional. To define the role of upregulated Bax in Treg apoptosis, we established a Tregs-specific Bax transgenic mouse model. Enforced expression of Bax in Tregs promotes Treg apoptosis triggered by IL-2 withdrawal and other apoptosis stimuli, suggesting pro-apoptotic role of highly expressed Bax in wild-type Tregs. Finally, higher expression of Bax in Tregs decreases the striking threshold of vascular inflammation due to the failure of suppression of inflammatory cells resulting from Treg apoptosis. These results have demonstrated the proof of principle that the modulation of Tregs apoptosis/survival could be used as a new therapeutic approach for inflammatory cardiovascular diseases.

Keywords: Regulatory T Cells, Apoptosis, Bax, Inflammation, Vasculitis

2. INTRODUCTION

CD4+CD25highFoxp3+ regulatory T cells (Tregs), comprising 5–10% of CD4+ T cells(1), exhibit potent immunosuppressive functions(2) in the regulation of autoimmunity and inflammatory atherosclerosis (3, 4). Naturally occurring Treg cells (thymus-generated, nTreg cells), as an independent subset, are engaged in the maintenance of immunological self-tolerance and inhibition of various immune responses (5) and inflammatory atherogenesis. nTregs (Tregs in the rest of paper) appear to have specific apoptosis pathways since Treg cells have higher susceptibility to apoptosis (6), especially to IL-2 withdrawal-induced apoptosis. Tregs are poor IL-2 producers(7), implying that insufficient paracrine IL-2 supply to Tregs in pathological conditions could be responsible for higher susceptibility of Tregs to apoptosis. However, intracellular regulation of IL-2 insufficiency-triggered Treg apoptosis remains poorly defined. The Bcl-2/Bcl-xL protein family members play a central role in the regulation of apoptosis(8). Recently, we identified a novel Bcl-xL-interacting anti-apoptotic protein, translationally controlled tumor protein (TCTP)(9). Although TCTP is not a Bcl-2/Bcl-xL family member, down-regulation of endogenous TCTP expression by antisense results in the increase of T cell apoptosis(9). The role of TCTP in promoting Treg survival is under intensive investigation. Our recent report showed that expression of a prototypic pro-apoptotic protein, Bax, in Bcl-2 family is higher in Tregs than in CD4+CD25− T cells(10), suggesting an important role of Bax protein in regulating Treg apoptosis. A recent report suggested that Bax does not have to adopt its final conformation to drive T cell death, which supports a functional significance of higher expression of Bax in inducing Treg apoptosis(11).

Tregs play an important role in controlling the pathogenesis of inflammatory atherosclerosis(3, 4). In addition, IL-2 knock-out mice have a deficiency in Tregs, and spontaneously develop autoimmune diseases including vasculitis(12). However, it remains to be determined if a deficiency in Treg generation in IL-2 knock-out mice, or higher susceptibility of Tregs to apoptosis induced by IL-2 deficiency, contributes to accelerated vasculitis. Since Tregs with high affinity IL-2 receptor have higher susceptibility to apoptosis in comparison to CD4+CD25− T cells, characterization of IL-2 withdrawal-Bax pathway in Tregs would be important in generating a substantial quantity of well-survived Tregs for Treg-based immune therapeutics(13). Therefore, three important questions remained to be answered toward this goal. First, whether high expression of Bax in Tregs is under regulation by an IL-2 receptor-initiated signaling; second, whether highly expressed Bax in Tregs is functional in driving Treg apoptosis; and third, whether higher expression of Bax in Tregs accelerates the development of vascular inflammation. To examine these questions, we established a mouse CD25 promoter(14)-directed Bax transgenic mouse model (Bax Tg). We found that Bax Tg resulted in enhanced apoptosis of Tregs. Interestingly, we also found that Treg apoptosis led to accelerated development of vasculitis presumably due to promotion of Treg apoptosis and failure in inhibiting inflammatory cells. These results have demonstrated the proof of principle that novel therapeutics can be developed for treating vasculitis and atherosclerosis via inhibiting Bax expression in Tregs and promoting survival of Tregs(15).

3. MATERIALS AND METHODS

3.1. Construction of CD25+ T cell-targeting mouse IL-2Rα promoter-Bax transgenic mice

Mouse IL-2 receptor α chain (CD25) promoter −2539 to +93 (GenBank Accession Number: M16398) vector pmIL2Rα-CAT1 (6.9 kb) was generously provided by P. Reichenbach and M. Nabholz(14). The construction of the CD25+ T cell targeting vector pCD25-Tg was described previously (10). The transgenic vector pCD25-Bax-Tg was verified by DNA sequencing by SeqWright Company (Houston, TX). The 3.818 kb transgenic DNA fragment “Nru I-CD25 promoter-C-Myc-Bax-Sex AI” was prepared by digesting the pCD25-Bax-Tg vector with three restriction enzymes, Nru I, Sex AI, and Pvu I (New England Biolabs, Ipswich, MA), gel-purified, and microinjected into zygotes from C57BL/6 mice in the Baylor College of Medicine Genetically Engineered Mouse Core. All animal experiments in this study were performed according to the US National Institutes of Health guideline and the protocols approved by Baylor College of Medicine and Temple University Institutional Animal Care and Use Committees.

3.2. PCR and RT-PCR

Transgenic mice were identified by PCR with mouse tail DNA as the templates using the special primers (Figure 2-B). The amplified PCR products were subcloned into TOPO TA plasmid (Invitrogen, Carlsbad, CA) and confirmed by DNA sequencing. Enforced expression of Bax in CD25+ T cell-specific manner in these transgenic mice was confirmed by RT-PCR using the primers (C-Myc primer and Bax anti-sense primer) that distinguish transgenic and endogenous RNA transcripts(16). All mice used in the experiments were age- and sex-matched. Total RNA isolation and RT-PCR were performed as previously reported(17).

Figure 2
Generation of TCTP transgenic mouse model. A. Bax transgenic construct. A c-myc expression tag-fused Bax cDNA was placed under the direction of mouse CD25 promoter. The locations of primers used for PCR detection of transgenic Bax DNA, and RT-PCR detection ...

3.3. Flow cytometric analysis

Single cell suspensions of samples were treated with ammonium chloride to remove erythrocytes, washed, and then stained with antibodies (Abs) for various cell markers. Cells (1 × 106) were suspended in 100 µl of PBS containing 2% BSA and stained with 1 µg of various fluorescent Abs for 30 min at 4°C, and analyzed on FACSCalibar (BD Bioscience, San Jose, CA). Forward and side scatter gatings were used to exclude debris from the analysis. Cells were stained with FITC-, PE-, or PE-Cy7-conjugated monoclonal Abs (mAbs) against: CD4, CD8a, TCRβ, CD3ε, and CD25 (BD Pharmingen, San Diego, CA). PE-, PE-Cy7- and FITC-conjugated rat and hamster IgG were used as controls.

3.4. Intracellular Staining for Bax and FOXP3

Bax-FITC antibody (Ab) and Anti-Foxp3 Ab were purchased from Santa Cruz Biotech (Santa Cruz, CA) and eBioscience (San Diego, CA), respectively. Intracellular staining of freshly isolated cells for Bax and Foxp3 was performed as previously described(10).

3.5. T Cell Activation

Mouse splenic T cells were prepared as previously reported(16) and activated by either plate-bound anti-CD3 (145.2C11 clone, 1 µg/ml, BD PharMingen) alone, or plate-bound anti-CD3 (1 µg/ml) and anti-CD28 (37.51 clone, 1 µg/ml, BD PharMingen) (16, 17).

3.6. Cell Culture and Induced Apoptosis In vitro

As normal culture condition with RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum (FBS, Hyclone, Logan, UT), mouse IL-2 (Sigma-Aldrich, St. Louis, MO) was added to the splenocytes culture at 5 ng/ml. IL-2 was withdrawn for 12 hours to induce apoptosis. After 12 and 24 hours, cell viabilities were determined by flow cytometry on the FACSCalibur flow cytometer with Annexin V-FITC Apoptosis Detection Kit (BD PharMingen)(18).

3.7. Perivascular cuff-injury induced vasculitis of femoral artery

The femoral artery was looped with a ligature and a non-flow obstructing polyethylene cuff (0.3 mm inner diameter, 0.70 mm outer diameter) was placed on the femur artery to induce stenosis, and closed with a ligature. Finally, the skin incision was closed with a running suture(19).

3.8. Histology

The images of lymphoid tissues were taken with a Zeiss Axioskopz Plus microscope (Oberkochen, Germany). The tissue areas in the images were analyzed by the software Image-Pro Plus 6.0 and used as the indices of the sizes of tissues as reported(20). Femoral arteries with cuff-induced stenosis were removed, snap frozen in liquid nitrogen, and stored at −80°C. Serial cryostatic sections (5-µm thick) were cut consecutively: hematoxylin-eosin (H&E)-stained slides were used to examine the vessel affected by induced vasculitis with a microscopy (Zeiss LSM 310; Zeiss).

4. RESULTS

4.1. Tregs have significantly higher expression of Bax and higher rates of apoptosis after IL-2 withdrawal

We first determined whether insufficient paracrine IL-2 supply to Tregs(7) could trigger upregulation of Bax expression and higher rates of Treg apoptosis. Based on CD25 expression levels, we gated splenic CD4+ T cells into three fractions, CD4+CD25− fraction, CD4+CD25low fraction, and CD4+CD25high fraction (Figure 1A). Since over 96% of CD4+CD25high T cells(21) express Treg-specific transcription factor FOXP3(22, 23), CD25high was used as a cell surface marker for Tregs in this study(24). The results showed that IL-2 withdrawal for 12 hours significantly upregulated apoptosis rates of wild-type CD4+CD25high Tregs from 11.6% (with IL-2 control) to 19.4% (Figure 1B). In comparison, the apoptosis rates of CD4+CD25− T cells were only increased from 2.5% (with IL-2 control) to 3.5%. In addition, the higher apoptosis rates of Tregs and CD4+CD25low cells were inhibited by a Bax-specific inhibitor from 19.4% and 17.1% to 15.4% and 11.0%, respectively, but not by negative inhibitor control (not shown), suggesting that Bax is functional in mediating IL-2 withdrawal-triggered Treg apoptosis. We then examined the issue, detected by FITC-conjugated anti-Bax monoclonal antibody as we reported(10), whether IL-2 withdrawal upregulates intracellular Bax expression in Tregs. The results showed that most (88% to 98%) of wild-type CD4+ T cells express low levels of Bax, as shown in the upper gates in each FACS plot (Figure 1C1). Interestingly, Treg fraction with higher Bax expression (e.g. higher fluorescence intensity, higher FI) was increased from 22.7% at 0 hour to 43.1% at 12 hours after IL-2 withdrawal (Figure 1C1, right panel and Figure 1C2) whereas CD4+CD25− T cell fraction with higher FI of Bax at 0 hour (7.8%) was not significantly changed at 12 hrs after IL-2 withdrawal (Figure 1C1, left panel and Figure 1C2). The results suggest that IL-2 withdrawal upregulated Bax expression in Tregs (Figure 1C1), which was correlated with higher apoptosis rates of Tregs induced by IL-2 withdrawal (Figure 1B). Furthermore, since tumor suppression transcription factor p53 promotes apoptosis by binding to Bax promoter and upregulating Bax expression(25), we asked whether upregulated expression of Bax in Tregs induced by IL-2 is mediated by p53 function. The results showed that upregulated expression of Bax in Tregs was inhibited by p53 inhibitor (Figure 1D1, right panel and Figure 1D2) from 37.5% (vehicle control) to 23.4%, suggesting that Bax upregulation triggered by IL-2 withdrawal is mediated via a transcription mechanism(26). Of note, it is well-known that Bax transcription is mediated by a p53 dependent pathway. However, inhibition of Bax upregulation by p53 inhibitor suggests that transcriptional mechanism plays an important role in Bax upregulation. Transgenic approach becomes only appropriate if the transcription of genes plays an important regulatory role in the expression of genes. Therefore, the results suggested the feasibility of using the transgenic approach to upregulate Bax expression to define the functional significance of upregulated Bax in Treg apoptosis. In addition, the results suggested the following working hypothesis: IL-2 withdrawal triggered Treg apoptosis is mediated by upregulated functional Bax (Figure 1E).

Figure 1
Association of IL-2 withdrawal-induced Bax upregulation and Treg apoptosis. A. Quantitation of wild-type splenic CD4+CD25− T cells, CD4+CD25low and CD4+CD25high Tregs by flow cytometry with PE-conjugated CD25 and PE-Cy7-conjugated CD4 antibodies. ...

4.2. Bax-Tg results in increased Bax expression in Tregs

We then used the transgenic approach to express Bax in Tregs under the direction of CD25 promoter (Figure 2-A), since CD25high is a reliable marker for Tregs. The detailed justification for use of CD25 promoter to direct the expression of Bax transgene (Tg), rather than other promoter, is presented in the Discussion. The results of genomic DNA PCR analysis with mouse tail DNAs showed that two founders of Bax Tg were generated (Figure 2-C). The RT-PCR analysis with RNAs prepared from three lymphoid tissues including thymus, lymph nodes (LN), spleen, and two non-lymphoid control tissues, liver and kidney, of Bax Tg showed that transgenic Bax transcripts were expressed in lymphoid tissues but not in non-lymphoid tissues of Bax Tg mice nor in all the tissues from wild-type littermate controls (Figure 2-D). To further confirm the expression of transgenic Bax protein, we used FACS analysis of Bax intracellular staining as reported for expression of other transgene(27). The results showed that Bax protein expression in CD4+CD25+ Tregs from Bax Tg mice was statistically higher than that in CD4+CD25+ Tregs from wild-type controls (Figure 2-E). The results were correlated with the cell expression patterns of CD25 gene promoter(14).

4.3. Reduced numbers of CD25+ thymocytes in Bax-Tg result in decreased positive selection of thymocytes

We determined whether reduced numbers of Tregs affect sizes and histology of lymphoid tissues in Bax Tg mice. The results showed that the sizes of Bax Tg thymus were not statistically different from that of wild-type thymus (p>0.05) (Figure 3-A). Similarly, the sizes of lymph nodes (LN) of Bax Tg mice were not significantly different from that in wild-type control mice (p>0.05) (Figure 3-B). In contrast, the sizes of Bax Tg spleens were larger than those of wild-type spleens (p<0.05) (Figure 3-C). These results suggest that Treg homeostasis plays a critical role in maintaining normal sizes of spleen(28).

Figure 3
Enlarged spleens of Bax transgenic mice with abnormal histological architecture. A. The sizes of six thymuses from wild-type control mice and from Bax transgenic mice were analyzed with digital photography followed by calculation of the surface areas ...

We examined the major subsets of thymocytes and T cells in spleen and lymph nodes in Bax Tg mice in comparison to those in wild-type control mice (Figure 4-A, upper panel). The results showed that CD4+ single positive (SP) thymocytes and CD8+ SP thymocytes were significantly reduced in Bax Tg mice by 46% and 62% ((WT-Bax Tg)/WT), respectively, at 3 weeks old. The results were correlated with a reduction of CD4+ SP thymocytes (67.2% of that in wild-type control mice) and CD8+ SP thymocytes (72.3% of that in wild-type control mice) observed in T cell-specific CD2 promoter Bax transgenic mice(29). These results also suggest that CD25+ thymocytes are a group of very important thymocytes facing positive selection. Correlated with the reduction of mature CD4+ SP and CD8+ SP, CD4+CD8+ double positive (DP) thymocytes were proportionally increased in Bax Tg mice. CD3+ thymocytes and CD4+CD8−CD25high thymocytes were also reduced, suggesting that overexpression of Bax in CD25high thymocytes result in decreased positive selection and thymocyte maturation from the CD4+CD8+ DP stages to the CD4+ SP stages. These results also suggest that CD25high Tregs share the same positive selection pathway with other non-Tregs thymocytes(30). In addition, splenic CD4+CD25high Tregs were decreased by 13% in Bax Tg mice in comparison to that of wild-type controls ((WT-Bax Tg)/WT) (Figure 4-A, middle panel). Of note, no significant changes were found in the percentages of major T cell subsets and B cells in spleens and lymph nodes from Bax Tg mice in comparison to that from wild-type control mice. Correlating with the decreased CD4+CD25high Tregs in Bax Tg spleen and lymph nodes (Figure 4A, lower panel), the expression of Foxp3+ in CD4+CD25high fraction in Bax Tg mice was decreased about 5% in comparison to that of wild-type mice (Figure 4-B). Since Foxp3 promotes apoptosis by itself(31), our results suggest that Bax may have a synergistic effect with Foxp3 in facilitating Treg apoptosis. Tregs from Bax Tg mice have a suppressive function similar to that from wild-type control mice by adding Tregs to inhibit the proliferation of carboxyfluoroscein succinimidyl ester (CFSE)-labeled wild-type CD4+CD25− T cell culture (not shown). In contrast, the percentages of splenic CD4+ T cells and CD8+ T cells were not significantly changed in Bax Tg mice from that of wild-type control mice. Our results correlate well with the previous report that the T cell decrease and thymocyte loss were obvious in 3 week-old mice, and could also be compensated in 9 week old Bax−/− deficient mice presumably via a putative mechanism of peripheral homeostatic expansion(18).

Figure 4
The phenotypic analysis of major T cell subsets in Bax transgenic mice. A. A representative phenotypic profile of major subsets of thymocytes, T cells in spleens and lymph nodes is presented. The experiments were repeated at least four times. B. FACS ...

4.4. Tregs from Bax Tg mice are more susceptible to apoptosis induced by T cell activation and IL-2 withdrawal

We then used the transgenic approach to express Bax in Tregs under the direction of CD25 promoter (Figure 2-A), since CD25high is a reliable marker for Tregs. We examined the issue of whether higher expression of Bax confers Tregs the higher susceptibility to apoptosis induced by T cell activation. The results showed that stimulation for 12 hours with plate-bound anti-CD3 antibodies (1 µg/ml) and anti-CD28 antibodies (1 µg/ml) induced more apoptosis (60.5%) to CD4+CD25high Tregs in Bax Tg mice in comparison to that (43.4%) of wild-type Tregs in the absence of IL-2 (Figure 5A, second panel). The apoptosis rates of CD4+CD25high Tregs from Bax Tg mice and wild-type control mice were even higher when stimulated with higher concentration (5 µg/ml) of anti-CD3 and anti-CD28 antibodies (Figure 5A, third panel). In addition, we determined whether higher expression of Bax confers Tregs the higher susceptibility to apoptosis induced by IL-2 withdrawal. The results showed that the apoptosis rates of CD4+CD25high Tregs were increased to 28.3% (Figure 5B, central panel) from the 14.5% of wild-type control mice in the absence of IL-2 for 12 hours (Figure 5B, left panel). The apoptosis rates in CD4+CD25high cells of Bax Tg mice was higher than that of CD4+CD25high cells from wild-type controls, suggesting that higher expression of Bax and IL-2 withdrawal has a synergistic effect in promoting Treg apoptosis. The sufficient IL-2 supply significantly inhibited Treg apoptosis of wild-type mice and Bax Tg mice (Figure 5B, right panel), suggesting that Bax plays a critical role in IL-2 withdrawal-triggered Treg apoptosis.

Figure 5
Higher susceptibility of Bax transgenic Tregs to apoptosis. A. Higher susceptibility of Bax transgenic Tregs to apoptosis induced by IL-2 withdrawal. Splenocytes from wild-type control mice (lower panel) and Bax transgenic mice (upper panel) were incubated ...

4.5. Higher expression of Bax in Tregs lowers striking threshold and accelerates development of experimental vasculitis

Tregs play an important role in suppressing the development of atherosclerotic plaques in ApoE−/− mice presumably via inhibition of atherogenic autoimmune inflammatory responses(3). The IL-2 expression, a key Treg survival factor, was absent in 50% of human atherosclerotic plaques(32), suggesting that insufficient paracrine IL-2 supply is an atherogenesis-associated pathological condition. However, the question remained unknown whether insufficient paracrine IL-2 supply triggered-Bax upregulation affects the development of experimental vasculitis in ApoE+/+ background. To examine this question, we adopted a well-characterized perivascular cuff-injury induced vasculitis(19) (Figs. 6A and B). The results showed that higher expression of Bax in Tregs significantly promoted inflammatory responses to loose placement of a non-flow obstructing cuff around the femoral artery, which led to partial closure of vasculitis-affected artery (Figure 6C). In contrast, loose placement of a non-flow obstructing cuff did not result in severe vasculitis in wild-type control mice (Figure 6C1). The statistical analysis of the ratios of vessel wall area over whole vessel section area showed that the areas in the vessel wall in Bax Tg mice, after placing the cuff, were significantly higher than those in the vessel wall in wild-type control mice under the same condition (p < 0.05) (Figs. 6C2 and 3), suggesting that inflamed vessel wall in Bax Tg after placing the cuff was significantly thicker than that in wild-type mice. Correlating with the thickened vessel wall, the infiltrated inflammatory cells in the vessel from Bax Tg after cuff placement were significantly higher than that in wild-type mice (Figure 6C4). Since it has been reported that CD4+CD25+ Tregs can exert direct suppressive effects on monocytes/macrophages in addition to suppressing effector T cells(33), therefore, our results suggest that the higher expression of Bax in Tregs reduces the striking threshold of inflammatory pathogenesis of vasculitis due to higher rates of Treg apoptosis and presumably failure in suppressing inflammatory cells (Figure 6D).

Figure 6
Decreased striking threshold of cuff-injured vasculitis in Bax transgenic mice. A. A schematic representation of the experimental model of non-constrictive cuff placement-induced vasculitis in a single side of the mouse femoral artery. B. Non-constrictive ...

5. DISCUSSION

Previous reports have shown that Tregs are highly susceptible to apoptosis(15, 34). Since Tregs generate poorly endogenous IL-2(7), Tregs require exogenous IL-2 for survival by expressing high levels of IL-2 receptor. However, IL-2-regulated Treg apoptotic pathways that underlie homeostatic mechanisms of Tregs remain poorly defined. Since homeostasis of Tregs is critical in maintaining immune tolerance and regulation of immune responses, elucidation of Treg-specific apoptotic pathways is significant(15). Our recent report showed that expression of pro-apoptotic protein Bax in Tregs is higher than that in CD4+CD25− T cells in the absence of any stimuli, which may be responsible for higher apoptosis rates of Tregs(10). This report indicates that exploration of the mechanism underlying physiopathologically higher expression of Bax in Tregs is of significance. Toward this goal, our current study has demonstrated, for the first time, the following findings: (a) IL-2 withdrawal induces upregulation of Bax presumably via a p53 dependent transcription pathway; (b) enforced expression of Bax in Tregs reduces positive selection of major subsets of mature thymocytes including Tregs, CD4+ single positive thymocytes and CD8+ single positive thymocytes, suggesting that Tregs share the same positive selection pathway with other thymocytes. Bax transgene also promotes Treg apoptosis triggered by IL-2 withdrawal and other apoptosis stimuli; (c) upregulated Bax in Tregs results in lymphoadenopathy-like histology in spleen, suggesting the importance of Tregs in maintaining normal splenic histological structure. Finally, our results show that higher expression of Bax in Tregs decreases the striking threshold of vascular inflammation due to promotion of Treg apoptosis and presumably failure in suppressing anti-vascular immune cell clones. Taken together, our data suggest that modulation of Tregs apoptosis/survival could be used as a therapeutic approach for inflammatory cardiovascular diseases(15).

nTregs are a special lineage of CD4+ T cells developed in thymus rather than a functional status, which makes a transgenic approach feasible. In addition to be a marker for Tregs, low levels but not high levels of CD25 can also be a T cell activation marker (30). However, up to 96% of CD4+CD25high Treg cells express FOXP3(21), suggesting that CD25high is an essential marker for FOXP3+ Tregs (31, 32). Our Bax transgenic data showed that transgenic Bax promotes higher apoptosis rates of CD25highFOXP3+ Tregs than that of CD4+CD25low. Of note, although FOXP3 plays a critical role in Treg development and function, FOXP3 per se promotes Treg apoptosis(31), and Foxp3 expression in activated T cells does not necessarily lead to acquisition of suppression function(35). These results suggest that use of CD25 promoter to generate Bax transgenic mice in this study was well justified.

Inflammatory atherosclerosis and vasculitis share the inflammatory responses against vessel wall components. Tregs play an important role in suppression of the inflammatory atherogenic process since depletion of Tregs accelerates atherosclerosis (3). Similarly, IL-2 knock-out mice have a deficiency in Tregs and spontaneously develop autoimmune diseases, including vasculitis(12). The reports suggest that IL-2 pathway is essential in maintaining survival of apoptosis-prone Tregs and suppressing inflammatory responses against vascular cell components. However, several important questions remain poorly defined including what mechanism underlies higher apoptosis of Tregs in the absence of a sufficient supply of IL-2; and whether Treg apoptosis pathway is therapeutically significant in modulating the pathogenesis of vascular inflammation. Our results demonstrate that Bax plays an important role in IL-2 withdrawal-induced apoptosis pathway of Tregs. Proliferation and migration of vascular smooth muscle cells (VSMCs) during neointima formation induced by arterial injury represent a critical component of restenosis after angioplasty of human coronary arteries and an important feature of atherosclerotic lesions(36). Peri-vascular cuff placement induces neointima formation, and this model represents the early features of atherosclerosis, such as proliferation of VSMCs but not foam cell formation. In this model, upregulated secretion of proinflammatory cytokines and increased inflammatory cell infiltration(37) may further lead to the exhausted availability of Tregs. As outlined in Figure 6D, higher expression of Bax in transgenic Tregs “amplifies” cuff-induced vascular inflammation. Future definition of the mechanisms of upregulation of Bax in Tregs may lead to development of new therapeutics for inflammatory vasculitis and atherosclerosis.

ACKNOWLEDGEMENTS

We are grateful to Drs. P. Reichenbach and M. Nabholz at the Swiss Cancer Center for providing mouse CD25 promoter. This work was partially supported by funds from National Institutes of Health grant AI054514 and Temple University Fund.

REFERENCES

1. Shevach EM, DiPaolo RA, Andersson J, Zhao DM, Stephens GL, Thornton AM. The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol Rev. 2006;212:60–73. [PubMed]
2. Horwitz DA, Gray JD, Zheng SG. The potential of human regulatory T cells generated ex vivo as a treatment for lupus and other chronic inflammatory diseases. Arthritis Res. 2002;4:241–246. [PMC free article] [PubMed]
3. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, Zoll J, Merval R, Esposito B, Cohen JL, Fisson S, Flavell RA, Hansson GK, Klatzmann D, Tedgui A, Mallat Z. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med. 2006;12:178–180. [PubMed]
4. Mor A, Planer D, Luboshits G, Afek A, Metzger S, Chajek-Shaul T, Keren G, George J. Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:893–900. [PubMed]
5. Yagi H, Nomura T, Nakamura K, Yamazaki S, Kitawaki T, Hori S, Maeda M, Onodera M, Uchiyama T, Fujii S, Sakaguchi S. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol. 2004;16:1643–1656. [PubMed]
6. Li L, Godfrey WR, Porter SB, Ge Y, June CH, Blazar BR, Boussiotis VA. CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. Blood. 2005;106:3068–3073. [PubMed]
7. de la Rosa M, Rutz S, Dorninger H, Scheffold A. Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur J Immunol. 2004;34:2480–2488. [PubMed]
8. Reed JC. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood. 2008;111:3322–3330. [PubMed]
9. Yang Y, Yang F, Xiong Z, Yan Y, Wang X, Nishino M, Mirkovic D, Nguyen J, Wang H, Yang XF. An N-terminal region of translationally controlled tumor protein is required for its antiapoptotic activity. Oncogene. 2005;24:4778–4788. [PubMed]
10. Yan Y, Chen Y, Yang F, Chen IH, Xiong Z, Wang J, Lachman LB, Wang H, Yang XF. HLA-A2.1-restricted T cells react to SEREX-defined tumor antigen CML66L and are suppressed by CD4+CD25+ regulatory T cells. Int J Immunopathol Pharmacol. 2007;20:75–89. [PMC free article] [PubMed]
11. Zhu Y, Liu X, Hildeman D, Peyerl FW, White J, Kushnir E, Kappler J, Marrack P. Bax does not have to adopt its final form to drive T cell death. J Exp Med. 2006;203:1147–1152. [PMC free article] [PubMed]
12. Sadlack B, Lohler J, Schorle H, Klebb G, Haber H, Sickel E, Noelle RJ, Horak I. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol. 1995;25:3053–3059. [PubMed]
13. Bluestone JA, Tang Q. Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells. Proc Natl Acad Sci U S A. 2004;101 Suppl 2:14622–14626. [PubMed]
14. Soldaini E, Pla M, Beermann F, Espel E, Corthesy P, Barange S, Waanders GA, MacDonald HR, Nabholz M. Mouse interleukin-2 receptor alpha gene expression. Delimitation of cis-acting regulatory elements in transgenic mice and by mapping of DNase-I hypersensitive sites. J Biol Chem. 1995;270:10733–10742. [PubMed]
15. Yang XF. Factors regulating apoptosis and homeostasis of CD4+CD25highFOXP3+ regulatory T cells are new therapeutic targets. Front Biosci. 2008;13:1472–1499. [PubMed]
16. Ye Q, Press B, Kissler S, Yang XF, Lu L, Bassing CH, Sleckman BP, Jansson M, Panoutsakopoulou V, Trimble LA, Alt FW, Cantor H. T cell costimulation through CD28 depends on induction of the Bcl-xgamma isoform: analysis of Bcl-xgamma-deficient mice. J Exp Med. 2002;196:87–95. [PMC free article] [PubMed]
17. Yang XF, Weber GF, Cantor H. A novel Bcl-x isoform connected to the T cell receptor regulates apoptosis in T cells. Immunity. 1997;7:629–639. [PubMed]
18. Rathmell JC, Lindsten T, Zong WX, Cinalli RM, Thompson CB. Deficiency in Bak and Bax perturbs thymic selection and lymphoid homeostasis. Nat Immunol. 2002;3:932–939. [PubMed]
19. Pires NMM, de Vries MR, Schepers A, Eefting D, Lardenoye J-WHP, Quax PHA. Perivascular cuff-, electronic and chemical injury-induced stenosis. In: Xu Q, editor. A Handbook of Mouse Models of Cardiovascular Disease. John Wiley & Sons, Ltd.; 2006.
20. El-Deiry WS, Sigman CC, Kelloff GJ. Imaging and oncologic drug development. J Clin Oncol. 2006;24:3261–3273. [PubMed]
21. Roncador G, Brown PJ, Maestre L, Hue S, Martinez-Torrecuadrada JL, Ling KL, Pratap S, Toms C, Fox BC, Cerundolo V, Powrie F, Banham AH. Analysis of FOXP3 protein expression in human CD4(+)CD25(+) regulatory T cells at the single-cell level. Eur J Immunol. 2005;35:1681–1691. [PubMed]
22. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. 2003;4:337–342. [PubMed]
23. Gavin M, Rudensky A. Control of immune homeostasis by naturally arising regulatory CD4(+) T cells. Curr Opin Immunol. 2003;15:690–696. [PubMed]
24. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol. 2001;167:1245–1253. [PubMed]
25. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293–299. [PubMed]
26. Grimes HL, Gilks CB, Chan TO, Porter S, Tsichlis PN. The Gfi-1 protooncoprotein represses Bax expression and inhibits T-cell death. Proc Natl Acad Sci U S A. 1996;93:14569–14573. [PubMed]
27. Chao DT, Linette GP, Boise LH, White LS, Thompson CB, Korsmeyer SJ. Bcl-XL and Bcl-2 repress a common pathway of cell death. J Exp Med. 1995;182:821–828. [PMC free article] [PubMed]
28. Godfrey VL, Wilkinson JE, Russell LB. X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. Am J Pathol. 1991;138:1379–1387. [PubMed]
29. Brady HJ, Gil-Gomez G, Kirberg J, Berns AJ. Bax alpha perturbs T cell development and affects cell cycle entry of T cells. Embo J. 1996;15:6991–7001. [PubMed]
30. Cozzo C, Lerman MA, Boesteanu A, Larkin J, 3rd, Jordan MS, Caton AJ. Selection of CD4+CD25+ regulatory T cells by self-peptides. Curr Top Microbiol Immunol. 2005;293:3–23. [PubMed]
31. Kasprowicz DJ, Droin N, Soper DM, Ramsdell F, Green DR, Ziegler SF. Dynamic regulation of FoxP3 expression controls the balance between CD4(+) T cell activation and cell death. Eur J Immunol. 2005;35:3424–3432. [PubMed]
32. Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, Hansson GK. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 1999;145:33–43. [PubMed]
33. Taams LS, van Amelsfort JM, Tiemessen MM, Jacobs KM, de Jong EC, Akbar AN, Bijlsma JW, Lafeber FP. Modulation of monocyte/macrophage function by human CD4+CD25+ regulatory T cells. Hum Immunol. 2005;66:222–230. [PubMed]
34. Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN. Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol. 2001;31:1122–1131. [PubMed]
35. Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, Toes RE. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol. 2007;37:129–138. [PubMed]
36. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res. 2004;95:858–866. [PubMed]
37. Koide S, Okazaki M, Tamura M, Ozumi K, Takatsu H, Kamezaki F, Tanimoto A, Tasaki H, Sasaguri Y, Nakashima Y, Otsuji Y. PTEN reduces cuff-induced neointima formation and proinflammatory cytokines. Am J Physiol Heart Circ Physiol. 2007;292:H2824–H2831. [PubMed]